COMP360 showed rapid and durable efficacy in chronic TRD, with about 40% of patients achieving meaningful response and 25% remission at 26 weeks after two doses. Safety was favorable, and commercial launch is targeted for the first half of 2027, pending regulatory milestones.

Based on

This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.